Recurrence Monitoring in NSCLC Using Circulating Tumor DNA
This research study is investigating the role of cell free tumor DNA profiling in determining disease relapse and/or progression for patients with advanced NSCLC.
Checked against the public recordLast updated Mar 23, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Scripps Translational Science Institute
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Treatment naïve biopsy confirmed not surgically resectable stage III or greater NSCLC * Baseline CT imaging available Exclusion Criteria: * Patients unable to undergo biopsy for initial tissue diagnosis * Patients who do not wish to pursue standard of care therapy * Patients with another diagnosis of malignancy
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Scripps Health/Scripps Clinic Hillcrest/Scripps Clinic Torrey PinesSan Diego, California
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 23, 2021. Always confirm current availability with the study team.